These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2035996)

  • 1. The diagnosis and treatment of prostate cancer.
    Andriole GL; Catalona WJ
    Annu Rev Med; 1991; 42():9-15. PubMed ID: 2035996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostate carcinoma--a current review].
    Schmid HP
    Schweiz Rundsch Med Prax; 1992 May; 81(20):647-53. PubMed ID: 1375772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H; Lau W; Bergstralh E; Blute ML
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostate cancer].
    Tanikawa T
    Rinsho Byori; 2001 Oct; 49(10):955-62. PubMed ID: 11769471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinics in prostate cancer].
    Sugimura Y
    Rinsho Byori; 2004 Jul; 52(7):604-10. PubMed ID: 15344560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer of the prostate.
    Bracarda S; de Cobelli O; Greco C; Prayer-Galetti T; Valdagni R; Gatta G; de Braud F; Bartsch G
    Crit Rev Oncol Hematol; 2005 Dec; 56(3):379-96. PubMed ID: 16310371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
    de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adenocarcinoma of the prostate].
    Dvorácek J
    Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice trends in the diagnosis and management of prostate cancer in the United States.
    Gee WF; Holtgrewe HL; Albertsen PC; Litwin MS; Manyak MJ; O'Leary MP; Painter MR
    J Urol; 1995 Jul; 154(1):207-8. PubMed ID: 7539862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS; Bianco FJ; Scardino PT; Eastham JA
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences between urologists in the United States and Canada in the approach to prostate cancer.
    Fleshner N; Rakovitch E; Klotz L
    J Urol; 2000 May; 163(5):1461-6. PubMed ID: 10751858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatic oncology.
    Narayan P; Jajodia P
    Clin Geriatr Med; 1990 Feb; 6(1):131-61. PubMed ID: 2405975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
    D'Amico AV; Chen MH; Roehl KA; Catalona WJ
    N Engl J Med; 2004 Jul; 351(2):125-35. PubMed ID: 15247353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.